Improving coagulation management in critical care

NLC seeks a Startup-CEO for a decision support system that enables critical care doctors to better assess, prevent and control the risk of thrombosis and bleeding incidents in ICU patients. The CEO will be responsible for building the team, advancing product development, establishing a strong IP position, and attracting financing. 

The Invention
Up to two-thirds of ICU patients have an impaired coagulation system and are at high risk of bleeding. Many of these patients also have multiple thrombosis risk factors and are therefore, although seemingly contradictory, at high risk of developing thrombotic complications as well. 

For instance, ICU patients are at high risk for developing venous thromboembolism (VTE incidence is 12%) and should therefore receive preventive anticoagulant therapy. However, of the critically ill patients receiving preventive treatment 80% has at least one episode of bleeding.  Another example, disseminated intravascular coagulation (DIC), occurs in 40% of sepsis patients and has a mortality of 40%. Therapy is regularly applied too late. The first clinical sign of DIC is often bleeding, when a diffuse micro-thrombotic episode has already caused damage to multiple organs.

Current diagnostics provide the intensivist little guidance on the optimal and timely corrective therapy for the individual patient. Clearly, for each ICU patient an accurate and personalized assessment of the bleeding and thrombosis risks is critical for improving the current situation.

Scientists at Philips have developed a decision support system for the physician. The smart algorithm, fueled by the patient’s data, the actual monitoring of clinical parameters and lab tests, models the coagulation system and predicts a patient’s  thrombosis and bleeding risks. It then reports to the clinician and suggests what personalized action is advised for the patient. The software model has been tested for various clinical applications and has shown to accurately indicate VTE and DIC risks in study populations. Next steps are to advance the model into attractive commercial propositions and to demonstrate the benefits in prospective clinical trials.

Job description Startup CEO
Following successful completion of the Formation phase for this project, the candidate will become the CEO leading the new venture. Working closely with the inventor and supported by NLC, the CEO will have the following key responsibilities:

  • Develop the commercial and overall business strategy for coagulation monitoring for ICU patients as the first application and develop opportunities in other disease areas with thrombosis and bleeding risks
  • Define the first MVP (minimum viable product) for use as a decision support system in the clinic
  • Organize and manage the development of the patient database and AI tools for the development of an improved medical protocol and individualised treatments. 
  • Direct ongoing product development in collaboration with the inventor
  • Raise financing for the new venture
  • Build up and manage the core team

Competencies of the ideal Startup-CEO

  • Entrepreneurial drive
  • Developing action oriented strategy
  • Executing plans, project management skills
  • Leading individuals and teams
  • Networking and influencing

    Prior experience

  • Developing and marketing of software based products and services in a critical care setting preferably including artificial intelligence
  • Professional experience to embody the required competencies and demonstrating track record
  • Carried overall responsibility for a company, business or (development) program
  • Academic qualifications

Other

  • The CEO will receive an equity-based remuneration and accept tying initial cash compensation to the success of founding and funding the company. Co-funding is possible and stimulated.

For more information please contact: Eva van Rooijen eva.vanrooijen@nlc.health